Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock?

TMDX rides OCS adoption and strong fourth-quarter results, but margin pressure raises questions for investors.

TransMedics is positioned for accelerating growth, with revenue expected to expand around 25% in 2026 and free cash flow breakeven by late 2026 or early 2027. TMDX is over the crest of its capex cycle, with investment pressures expected to ease, supporting margin expansion toward a 30% target by 2028. Despite a weak balance sheet and potential for 15% shareholder dilution in 2026, I remain bullish as long as revenue growth stays above 20% y/y.

TransMedics has transitioned into a fundamentally strong, profitable growth story with reduced volatility and clear operational leverage. TMDX delivered a robust Q4, exceeding revenue and earnings estimates, with 32% Y/Y growth and expanding operating margins by over 610 bps. Management guides for 20-25% revenue growth in 2026, with Liver segment dominance and significant upside potential from Heart, Lung, and Kidney programs.

Five of the Fund's 10 equity sectors made a positive impact on calendar year performance, led by Industrials, Financials, and Information Technology. Alamos Gold's positive earnings outlook, a renewed stock buyback program, and rising gold prices all helped its stock to climb throughout 2025. Management reported a 48% increase in total revenue for 1Q25 compared to 1Q24, driven by OCS liver and heart transplants.

TransMedics remains the top dog in its industry and may have a widening moat. The founder-led company's shares have risen eightfold since 2019.

These four tickers aren't hype stocks; they're the plumbing in solid industries. Axon Enterprise has switching costs; Vertiv is embedded in AI infrastructure; TransMedics controls a life-critical logistics network; and Fair Isaac has regulatory entrenchment and pricing power.